Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ultrapure dialysate.

Richard A Ward1

  • 1Kidney Disease Program, Department of Medicine, University of Louisville, 615 S. Preston Street, Louisville, KY 40202-1718, USA. richard.ward@louisville.edu

Seminars in Dialysis
|January 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding.

Communications chemistry·2025
Same author

Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding.

Communications chemistry·2025
Same author

Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations.

Journal of medicinal chemistry·2025
Same author

Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.

Journal of medicinal chemistry·2024
Same author

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.

Journal of medicinal chemistry·2024
Same author

Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.

ACS medicinal chemistry letters·2024
Same journal

Intracardiac Vascular Access for Hemodialysis Despite Associated Ascending Aortic Aneurysm.

Seminars in dialysis·2026
Same journal

Measures of Equivalent Hemodialysis Urea Clearance and Their Proposed Utility for Monitoring Adequacy.

Seminars in dialysis·2026
Same journal

Risk of Serious Adverse Events and Death With Low-Dose Methotrexate Versus Hydroxychloroquine in Adults Receiving Dialysis.

Seminars in dialysis·2026
Same journal

Severe Hematoma Following Initial Arteriovenous Fistula Puncture in a Hemodialysis Patient, Emphasizing Thoracic Outlet Syndrome: A Case Report.

Seminars in dialysis·2026
Same journal

Phosphate Kinetic Modeling in Patients Treated With Hemodialysis or Hemodiafiltration: A Prospective, Multicenter, Cross-Sectional Study.

Seminars in dialysis·2026
Same journal

Impact of Expanded Hemodialysis on Inflammation and Iron Metabolism in Chronic Hemodialysis Patients.

Seminars in dialysis·2026
See all related articles

Ultrapure dialysate may reduce chronic inflammation in hemodialysis patients, but more research is needed to confirm benefits and cost-effectiveness for patient outcomes.

Area of Science:

  • Nephrology
  • Biomedical Engineering
  • Immunology

Background:

  • Current hemodialysis dialysate quality standards (100-200 CFU/ml bacteria, 0.25-2 EU/ml endotoxin) prevent acute pyrogenic reactions.
  • Accumulating evidence suggests these standards may not prevent chronic inflammation in hemodialysis patients.
  • Bacterial fragments can cross standard dialysis membranes, potentially triggering immune responses.

Purpose of the Study:

  • To evaluate the impact of ultrapure dialysate on chronic inflammation markers and clinical outcomes in hemodialysis patients.
  • To compare the effects of ultrapure dialysate versus standard-quality dialysate.

Main Methods:

  • In vitro studies assessing membrane permeability to bacterial products.
  • Clinical studies comparing inflammatory markers and acute phase reactants between patients using ultrapure and standard dialysate.

Related Experiment Videos

  • Observational studies linking dialysate purity to clinical outcomes.

    • Main Results:

    • Ultrapure dialysate (bacteria < 0.1 CFU/ml, endotoxin < 0.03 EU/ml) is associated with lower inflammatory markers.
    • Observational data suggest potential improvements with ultrapure dialysate, including better nutritional status, erythropoietin response, preserved renal function, reduced cardiovascular morbidity, and less beta(2)-microglobulin amyloidosis.
    • No cause-and-effect relationship has been established, and concentration-dependent effects remain unclear.

    Conclusions:

    • While ultrapure dialysate shows promise in reducing inflammation and potentially improving outcomes, controlled clinical trials are necessary.
    • Further research is needed to determine the cost-effectiveness of implementing ultrapure dialysate in routine clinical practice.
    • The precise role of dialysate purity as an inflammation trigger requires further elucidation.